MDSC Mediscience Technology Corp. Developing Cancer Detection Instrument for Analyzing Surgical Breast Tissue Specimens at Point-of-Care
Mediscience Technology Corp. Developing Cancer Detection Instrument for Analyzing Surgical Breast Tissue Specimens at Point-of-Care
CHERRY HILL, N.J.
Mediscience Technology
Michael Engelhart, 201-818-0050
Mengelhart@MediScience.com
or
Media:
Investor Relations Group
Janet Vasquez/ Lynn Granito, 212-825-3210
or
Investor Relations:
Investor Relations Group
Erik Lux/Adam Holdsworth/John Nesbett, 212-825-3210
Mediscience Technology, Corp. (OTCBB:MDSC) announced that it is in development of an adjunctive instrument called the Cancer Detection (CD) Map, to facilitate the acquisition of fluorescence images from surgical breast specimens (ex vivo) following lumpectomies and surgical procedures.
The instrument will be used to define the margins of tumors at the point-of-care, thus allowing the physician to obtain greater success in achieving clear margins in real time during cancer surgery without the use of extrinsic dyes, drugs or other invasive agents. The CD-Map is highly sensitive and can acquire images in less than one second. Zoom capability allows the CD-Map to acquire images over an area that can vary from sub-cm to several cm with a resolution better than 100 mm.
"We have performed prior studies on ex vivo tissue specimens and have demonstrated that fluorescence images acquired with the CD-Map can define regions of cancer, as well as identify other structures (i.e. veins, glands) inside tissue," said Michael Engelhart President and Chief Operating Officer. "We believe the CD-Map has the potential to greatly enhance patient outcomes at point-of-care through the delivery of clear margins confirmed through a pathology report," he added.
The CD-Map is a UV/visible fluorescence imaging system designed to gain image emission from native fluorophors in tissue. A tunable light source and movable filters permit the acquisition of images at multiple combinations of emission and excitation wavelengths. Intensity ratio maps are computer generated from the fluorescence images and either the intensity images or pseudo-color ratio images are displayed.
About Mediscience Technology
Mediscience Technology Corporation is engaged in the design, development and commercialization of medical devices that detect cancer and physiological change using frequencies of light that are emitted, scattered and absorbed to distinguish malignant, precancerous, or benign tissues from normal tissues. Mediscience's exclusive protected noninvasive technology combines the advantages of real-time results with enhanced diagnostic sensitivity and specificity compared with other methods of cancer detection.
Investor Notice:
Certain of the matters discussed in this announcement contain forward-looking statements that involve material risks to and uncertainties in the parties/company's business that may cause actual results to differ materially from those anticipated by the statements made herein. Such risks and uncertainties include among other things, the availability of financing, the parties/company's ability to implement its long-range business plan for the joint or independent development of various applications of its technology/IP; the company's ability to enter into future agreements with any necessary marketing and/or distribution partners; the impact of competition, the obtaining and maintenance of any necessary US regulatory i.e. FDA clearances applicable to applications of the company's technology; and management of growth and other risks and uncertainties that may be detailed from time to time in the parties/company's reports filed with the Securities and Exchange Commission. This disclosure is intended to satisfy: SEC Section 6, 6.01 Regulation FD, disclosure and Section 7 and 7.0 as well as all applicable and presently effective Sarbanes-Oxley disclosure requirements under Regulation G.
